ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers [Yahoo! Finance]
ArriVent BioPharma, Inc. (AVBP)
Company Research
Source: Yahoo! Finance
Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancers First Investigational New Drug (IND) submission planned for 1H 2025 Expands ArriVent's growing pipeline of next-generation ADCs NEWTOWN SQUARE, Pa. and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) for MRG007, an antibody-drug conjugate (ADC) that can target several gastrointestinal (GI) cancers. Under the terms of the agreement, ArriVent obtains the exclusive rights to develop and commercialize MRG007 worldwide outside of Greater China which includes mainland China, Hong Kong, Macau and Taiwan. "We believe MRG007 is a potential be
Show less
Read more
Impact Snapshot
Event Time:
AVBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVBP alerts
High impacting ArriVent BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AVBP
News
- Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443BPR Newswire
- ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.MarketBeat
- ArriVent BioPharma (NASDAQ:AVBP) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.MarketBeat
- ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Truist Financial Corporation to a "strong-buy" rating.MarketBeat
AVBP
Earnings
- 11/10/25 - Miss
AVBP
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- AVBP's page on the SEC website